Human Genome Sciences CEO Is Former TAP President Thomas Watkins
This article was originally published in The Pink Sheet Daily
Executive Summary
Watkins joins HGS after serving as head of TAP Pharmaceuticals for six years. HGS focused its CEO search on candidates with late-stage product development experience; the firm's lead candidate LymphoStat-B is in Phase II for RA and lupus.
You may also be interested in...
GSK Sweetens Early-Stage Diabetes Pipeline With HGS’ Albugon
The preclinical peptide hormone will likely be developed for Type-2 diabetes. Human Genome Sciences believes potential advantage with Albugon is prolonged half-life.
Human Genome Sciences Names Chairman
Argeris Karabelis, PhD, will become chairman of Human Genome Sciences' board of directors effective Oct. 17
TAP President Will Be Former Sales VP Alan MacKenzie
MacKenzie is rejoining TAP two months after being acquitted on charges of conspiracy to pay kickbacks to prescribers and defraud Medicaid in the U.S. government's investigation into Lupron marketing. Upon expiry of his term, current TAP President Thomas Watkins will rejoin Abbott in a senior management role.